Cardiovasculer diseases are the most common reason for morbidity and mortality in the world. Smoking and obesity are among the most important avoidable reasons for these diseases. However, in Turkey, there are not enough studies about the effect of obesity (central and androgenic) on insulin levels of smokers. With this aim; oral glucose tolerance test (OGTT) was performed on 84 patients who meet the study criteria among 211 patients treated at the second internal diseases clinic of Taksim Hospital between November 1997 and May 1998, who were volunteers, smokers and older than 18. In addition, the total cholesterol, HDL, LDL and triglicerid levels of these patiens were checked. Heights, weights and waist circumferences of patients were measured. From these datas, body mass indexes (BMI) and waist circumferences (WC) were calculated. Nicotine addiction levels of patients were evaluated by Fagerstrom Nicotine Dependency Test (FNDT) and package/year amounts were calculated. According to the results based on the data obtained from the studies, no difference were determined (p>0.05), in ages, FNDT scores, insulin, TC, LDL and HDL levels between overweighted and normal weighted patients. On the other hand; there was statistically significant difference between two groups in BMI values, WC measurements (between different genders) and TG levels. In the regression analysis; BMI [OR: 1.512, (95% CI min=0.928, max=2.069)] and WC [OR: 1.912, (95% CI min=1.051, max=2.125)] was founded as a risk factor for the insulin increment. Additional information about the subject for the large participation cross-sectional studies. More action about life style modification (smoking cessation and an effective weight control) may increase risk of cardiovascular diseases in populations. |
Journal Section | Internal Medical Sciences |
---|---|
Authors | |
Publication Date | July 20, 2017 |
Submission Date | October 14, 2016 |
Published in Issue | Year 2017 Volume: 34 Issue: 1 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.